Compare Stocks: MAZE, KNSA, ORKA, and COGT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$34.76 -0.5%	$38.50	$11.60 ▼ $43.73	$6.06B	0.31	1.66 million shs	784,078 shs
KNSA Kiniksa Pharmaceuticals International	$77.91 -3.2%	$71.98	$35.12 ▼ $82.94	$6.08B	0.09	433,390 shs	429,634 shs
MAZE Maze Therapeutics	$26.21 +1.3%	$28.69	$14.27 ▼ $53.65	$1.44B	2.17	397,261 shs	273,267 shs
ORKA Oruka Therapeutics	$92.51 +1.7%	$95.24	$14.66 ▼ $115.51	$6.02B	-0.34	806,943 shs	600,469 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	-0.54%	+0.26%	-17.80%	+12.06%	+165.75%
KNSA Kiniksa Pharmaceuticals International	-3.18%	-0.22%	-0.22%	+60.90%	+119.59%
MAZE Maze Therapeutics	+1.31%	-4.48%	-5.75%	+7.99%	+72.55%
ORKA Oruka Therapeutics	+1.67%	+1.50%	-4.82%	+53.82%	+499.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$34.76 -0.5%	$38.50	$11.60 ▼ $43.73	$6.06B	0.31	1.66 million shs	784,078 shs
KNSA Kiniksa Pharmaceuticals International	$77.91 -3.2%	$71.98	$35.12 ▼ $82.94	$6.08B	0.09	433,390 shs	429,634 shs
MAZE Maze Therapeutics	$26.21 +1.3%	$28.69	$14.27 ▼ $53.65	$1.44B	2.17	397,261 shs	273,267 shs
ORKA Oruka Therapeutics	$92.51 +1.7%	$95.24	$14.66 ▼ $115.51	$6.02B	-0.34	806,943 shs	600,469 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	-0.54%	+0.26%	-17.80%	+12.06%	+165.75%
KNSA Kiniksa Pharmaceuticals International	-3.18%	-0.22%	-0.22%	+60.90%	+119.59%
MAZE Maze Therapeutics	+1.31%	-4.48%	-5.75%	+7.99%	+72.55%
ORKA Oruka Therapeutics	+1.67%	+1.50%	-4.82%	+53.82%	+499.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COGT Cogent Biosciences	2.75	Moderate Buy	$51.56	48.32% Upside
KNSA Kiniksa Pharmaceuticals International	2.80	Moderate Buy	$87.38	12.15% Upside
MAZE Maze Therapeutics	3.08	Buy	$66.00	151.81% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$133.00	43.77% Upside

Current Analyst Ratings Breakdown

Latest MAZE, KNSA, ORKA, and COGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ORKA Oruka Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/3/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/24/2026	MAZE Maze Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	COGT Cogent Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$52.00 ➝ $55.00
8/13/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/12/2026	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $52.00
8/12/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
8/11/2026	ORKA Oruka Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
8/11/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00
8/11/2026	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$151.00
8/3/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$2.69 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$840.85M	7.23	$0.77 per share	101.38	$8.38 per share	9.30
MAZE Maze Therapeutics	$167.50M	8.69	N/A	N/A	$8.16 per share	3.21
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$16.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COGT Cogent Biosciences	-$328.94M	-$2.16	N/A	N/A	N/A	N/A	-84.47%	-47.72%	11/6/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	80.32	37.64	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)

Latest MAZE, KNSA, ORKA, and COGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COGT Cogent Biosciences	0.48	13.57	13.57
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
MAZE Maze Therapeutics	0.09	18.31	18.31
ORKA Oruka Therapeutics	N/A	38.51	38.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COGT Cogent Biosciences	N/A
KNSA Kiniksa Pharmaceuticals International	53.95%
MAZE Maze Therapeutics	N/A
ORKA Oruka Therapeutics	56.44%

Insider Ownership

Company	Insider Ownership
COGT Cogent Biosciences	6.59%
KNSA Kiniksa Pharmaceuticals International	51.98%
MAZE Maze Therapeutics	5.30%
ORKA Oruka Therapeutics	23.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COGT Cogent Biosciences	80	173.53 million	162.09 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	78.02 million	37.47 million	Optionable
MAZE Maze Therapeutics	121	55.55 million	52.61 million	N/A
ORKA Oruka Therapeutics	N/A	66.21 million	50.66 million	N/A

MAZE, KNSA, ORKA, and COGT Headlines

Recent News About These Companies

HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

September 5 at 2:18 AM | americanbankingnews.com

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $6,887,250.00 in Stock

September 4 at 4:09 AM | americanbankingnews.com

HC Wainwright Reiterates "Buy" Rating for Oruka Therapeutics (NASDAQ:ORKA)

September 3 at 8:11 AM | marketbeat.com

278,164 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Braidwell LP

September 3 at 4:23 AM | marketbeat.com

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells 75,000 Shares of Stock

September 2 at 5:07 AM | insidertrades.com

Bank of New York Mellon Corp Invests $13.41 Million in Oruka Therapeutics, Inc. $ORKA

September 2 at 3:14 AM | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 75,000 Shares

September 1, 2026 | marketbeat.com

Alyeska Investment Group L.P. Sells 97,119 Shares of Oruka Therapeutics, Inc. $ORKA

September 1, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Trading Down 5% - Time to Sell?

August 31, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Acquires New Shares in Oruka Therapeutics, Inc. $ORKA

August 31, 2026 | marketbeat.com

Freestone Grove Partners LP Takes $2.13 Million Position in Oruka Therapeutics, Inc. $ORKA

August 29, 2026 | marketbeat.com

Bank of America Corp DE Sells 39,181 Shares of Oruka Therapeutics, Inc. $ORKA

August 29, 2026 | marketbeat.com

ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know

August 28, 2026 | zacks.com

Palo Alto Investors LP Buys New Stake in Oruka Therapeutics, Inc. $ORKA

August 28, 2026 | marketbeat.com

Jupiter Topco LLC Takes Position in Oruka Therapeutics, Inc. $ORKA

August 27, 2026 | marketbeat.com

Artia Global Partners LP Purchases New Holdings in Oruka Therapeutics, Inc. $ORKA

August 27, 2026 | marketbeat.com

J. Goldman & Co LP Makes New Investment in Oruka Therapeutics, Inc. $ORKA

August 26, 2026 | marketbeat.com

20,840 Shares in Oruka Therapeutics, Inc. $ORKA Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Oruka Therapeutics Names Chief Commercial Officer

August 25, 2026 | finance.yahoo.com

113,188 Shares in Oruka Therapeutics, Inc. $ORKA Purchased by Parkman Healthcare Partners LLC

August 25, 2026 | marketbeat.com

BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE, KNSA, ORKA, and COGT Company Descriptions

Cogent Biosciences NASDAQ:COGT

$34.76 -0.19 (-0.54%)

As of 09/4/2026 04:00 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$77.91 -2.56 (-3.18%)

As of 09/4/2026 04:00 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Maze Therapeutics NASDAQ:MAZE

$26.21 +0.34 (+1.31%)

As of 09/4/2026 04:00 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Oruka Therapeutics NASDAQ:ORKA

$92.51 +1.52 (+1.67%)

As of 09/4/2026 04:00 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAZE, KNSA, ORKA, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAZE, KNSA, ORKA, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAZE, KNSA, ORKA, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE, KNSA, ORKA, and COGT Company Descriptions

Cogent Biosciences NASDAQ:COGT

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Maze Therapeutics NASDAQ:MAZE

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAZE, KNSA, ORKA, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAZE, KNSA, ORKA, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAZE, KNSA, ORKA, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE, KNSA, ORKA, and COGT Company Descriptions

Cogent Biosciences NASDAQ:COGT

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Maze Therapeutics NASDAQ:MAZE

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools